Jeffrey T. Jensen, M.D., M.P.H.

  • Professor of Obstetrics and Gynecology, School of Medicine
  • Professor, Oregon National Primate Research Center
  • Vice Chair, Research, Obstetrics and Gynecology, School of Medicine
  • Director of the Women's Health Research Unit, Center for Women's Health, School of Medicine
  • Leon Speroff, M.D. Professor of Obstetrics & Gynecology

Biography

Jeffrey T. Jensen, M.D., M.P.H. is the Leon Speroff Professor and Vice Chair for Research in the Department of Ob/Gyn, Professor of Public Health and Preventive Medicine at OHSU and a Core Scientist at the Oregon National Primate Research Center (ONPRC). Dr. Jensen received a B.S. in Biology from Stanford University, an MD from Emory University and his M.P.H. from the University of Washington. He completed an internship at Santa Clara Valley Medical Center and a residency in obstetrics and gynecology at OHSU. Following residency training, he served four years in the United States Navy, and joined the faculty at OHSU in 1992.

Dr. Jensen’s career has been devoted to the improvement of human health and society through the promotion of safe, effective methods of contraception so that every baby is wanted and planned. As a clinician-scientist with more than 20 years of experience, his efforts encompass clinical care, clinical research and translational research.

He is the Director of the Women’s Health Research Unit at OHSU, and PI of the NICHD-funded Contraception Clinical Trials Network (CCTN). At ONPRC, he is Director of the Bill & Melinda Gates Foundation-funded Oregon Permanent Contraception Research Center (OPERM). His lab investigates novel contraceptive strategies using the nonhuman primate model. Current projects include the identification of oocyte-specific contraceptive agents, and nonsurgical methods of permanent contraception. He collaborates with CONRAD, FHI360, and the Population Council. He has served as a consultant or on advisory boards for several pharmaceutical companies, including Abbvie, Agile Pharmaceuticals, Bayer Healthcare, CooperSurgical, Evofem, Merck, HRA Pharma, MicroChips, ContraMed, and Wyeth. He is a well-regarded international speaker on contraception and serves as a Deputy Editor for the journal Contraception.

Education and training

  • Degrees

    • M.D., 1980, Emory University
    • M.P.H., 1997, University of Washington

  • Internship

    • Santa Clara Valley Medical Center, Flexible, 1985

  • Residency

    • Obstetrics and gynecology, Oregon Health & Science University, 1988

  • Certifications

    • American Board of Obstetrics and Gynecology

Memberships and associations:

  • American Congress of Obstetricians and Gynecologists

Publications

Elsevier pure profile

Selected publications

  • Hanna CB, Yao S, Martin M, Schönbrunn E, Georg GI, Jensen JT, et al. Identification and Screening of Selective WEE2 Inhibitors to Develop Non-Hormonal Contraceptives that Specifically Target Meiosis. ChemistrySelect. 2019;4(45):13363-9. PMCID: PMC7079731
  • Jensen JT, Edelman AB, Chen BA, Archer DF, et al. Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone(R) and estradiol: pharmacokinetics from a dose-finding study. Contraception. 2018;97(5):422-7. PMCID: PMC5948142 
  • Zhu JY, Cuellar RA, Berndt N, Lee HE, Olesen SH, Martin MP, Jensen JT, et al. Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors. J Med Chem. 2017;60(18):7863-75. PMCID: PMC6200136
  • Jensen JT, Hanna C, Yao S, Thompson E, Bauer C, Slayden OD. Transcervical administration of polidocanol foam prevents pregnancy in female baboons. Contraception. 2016; 94:527-533. PMCID: PMC5083254
  • Edelman AB, Cherala G, Blue SW, Erikson DW, Jensen JT. Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. Contraception. 2016; 94:52-57. PMC4944814
  • Jensen JT, Hanna C, Yao S, Bauer C, Morgan TK, Slayden OD. Characterization of tubal occlusion after transcervical polidocanol foam (PF) infusion in baboons. Contraception. 2015; 92:96-102. PMCID: PMC4521910
  • Jensen JT, Hanna C, Yao S, Micks E, Edelman A, Holden L, Slayden OD. Blockade of tubal patency following transcervical administration of polidocanol foam: initial studies in rhesus macaques. Contraception. 2014; 89:540-549. PMCID: PMC4033706

Publications

  • Double dosing ulipristal acetate emergency contraception for individuals with obesity

    BMJ Sexual and Reproductive Health
    1. Alison Edelman
    2. Jon D. Hennebold
    3. Kise Bond
    4. Jeong Y. Lim
    5. Ganesh Cherala
    6. Steven W. Blue
    7. Shawn P. Kraft
    8. David W. Erikson
    9. David Archer
    10. Jeffery Jensen

  • Emergency contraception for individuals weighing 80 kg or greater

    Contraception
    1. Alison Edelman
    2. Jeffrey T. Jensen
    3. Jill Brown
    4. Michael Thomas
    5. David F. Archer
    6. Courtney A. Schreiber
    7. Stephanie Teal
    8. Carolyn Westhoff
    9. Clint Dart
    10. Diana L. Blithe

  • Safety testing of Ovaprene

    Contraception
    1. Christine Mauck
    2. Andrea Thurman
    3. Jeffrey T. Jensen
    4. Courtney A. Schreiber
    5. Jeff Baker
    6. Melody Y. Hou
    7. Steven Chavoustie
    8. Clint Dart
    9. Hongsheng Wu
    10. Jacques Ravel
    11. Pawel Gajer
    12. Betsy C. Herold
    13. Terry Jacot
    14. Nadene Zack
    15. Jessica Hatheway
    16. David Friend

  • Successful postcoital testing of Ovaprene

    Contraception
    1. Christine Mauck
    2. Andrea Thurman
    3. Jeffrey T. Jensen
    4. Courtney A. Schreiber
    5. Jeff Baker
    6. Melody Y. Hou
    7. Steven Chavoustie
    8. Clint Dart
    9. Hongsheng Wu
    10. Nadene Zack
    11. Jessica Hatheway
    12. David Friend

  • The Levonorgestrel-Releasing Intrauterine Device as Emergency Contraception

    Obstetrics and gynecology
    1. Shaalini Ramanadhan
    2. Jeffrey Jensen

  • Use of serum evaluation of contraceptive and ovarian hormones to assess reduced risk of pregnancy among women presenting for emergency contraception in a multicenter clinical trial

    Contraception
    1. Jeffrey T. Jensen
    2. Alison Edelman
    3. Carolyn L. Westhoff
    4. Coutney A. Schreiber
    5. David F. Archer
    6. Stephanie Teal
    7. Michael Thomas
    8. Jill Brown
    9. Diana L. Blithe

  • Changes in hair cortisol concentration in intrauterine device initiators

    Contraception
    1. Nora Doty
    2. Ethan Beckley
    3. Bharti Garg
    4. Sumiko Maristany
    5. David W. Erikson
    6. Jeffrey T. Jensen

  • Combined Oral Contraceptive Adherence and Pregnancy Rates

    Obstetrics and gynecology
    1. Mitchell D. Creinin
    2. Jeffrey T. Jensen
    3. Melissa J. Chen
    4. Amanda Black
    5. Dustin Costescu
    6. Jean Michel Foidart

  • Development and validation of an expanded panel of progestins using liquid chromatography-tandem triple quadrupole mass spectrometry to monitor protocol compliance in hormonal contraceptive pharmacokinetic/pharmacodynamic studies

    Contraception
    1. Jeffrey T. Jensen
    2. Bethany T. Waites
    3. Emily R. Boniface
    4. Sara McCrimmon
    5. Steven Blue
    6. David W. Erikson

  • Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg

    Contraception
    1. Jeffrey T. Jensen
    2. Isabel Reinecke
    3. Teun M. Post
    4. Eeva Lukkari-Lax
    5. Birte M. Hofmann

  • Heavy Menstrual Bleeding Treatment With a Levonorgestrel 52-mg Intrauterine Device

    Obstetrics and gynecology
    1. Mitchell D. Creinin
    2. Kurt T. Barnhart
    3. Lori M. Gawron
    4. David Eisenberg
    5. R. Garn Mabey
    6. Jeffrey T. Jensen

  • Hormonal regulation of non-cystic fibrosis transmembrane conductance regulator ion channels in the endocervix

    F and S Science
    1. Mackenzie Roberts
    2. Shan Yao
    3. Shuhao Wei
    4. Jeffrey T. Jensen
    5. Leo Han

  • OHSU Employees’ Opinions of Receipt of Clinical Care and Participation in Clinical Research at Place of Employment

    Accountability in Research
    1. Morinne Osborne
    2. Emily Boniface
    3. Marcella Messerle Forbes
    4. Jeffrey Jensen

  • Satisfaction with a Segesterone Acetate and Ethinyl Estradiol Contraceptive Vaginal System Among Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring Users

    Journal of Women's Health
    1. Jeffrey T. Jensen
    2. David F. Archer
    3. Carolyn L. Westhoff
    4. Anita L. Nelson
    5. Shelli Graham
    6. Brian Bernick

  • Treatment of unfavorable bleeding patterns in contraceptive implant users

    American journal of obstetrics and gynecology
    1. Alison Edelman
    2. Emily Boniface
    3. Kaitlin Schrote
    4. Marci Messerle-Forbes
    5. Andrea O'Donnell
    6. Jeffrey T. Jensen
    7. Leo Han

  • Continuation rates of two different-sized copper intrauterine devices among nulliparous women

    EClinicalMedicine
    1. David Hubacher
    2. Courtney A. Schreiber
    3. David K. Turok
    4. Jeffrey T. Jensen
    5. Mitchell D. Creinin
    6. Kavita Nanda
    7. Katharine O.Connell White
    8. Ila Dayananda
    9. Stephanie B. Teal
    10. Pai Lien Chen
    11. Beatrice A. Chen
    12. Alisa B. Goldberg
    13. Jennifer L. Kerns
    14. Clint Dart
    15. Anita L. Nelson
    16. Michael A. Thomas
    17. David F. Archer
    18. Jill E. Brown
    19. Paula M. Castaño
    20. Anne E. Burke
    21. Bliss Kaneshiro
    22. Diana L. Blithe

  • Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years

    American journal of obstetrics and gynecology
    1. Jeffrey T. Jensen
    2. Eeva Lukkari-Lax
    3. Andrea Schulze
    4. Yesmean Wahdan
    5. Marco Serrani
    6. Robin Kroll

  • Double Dosing Levonorgestrel-Based Emergency Contraception for Individuals With Obesity

    Obstetrics and gynecology
    1. Alison B. Edelman
    2. Jon D. Hennebold
    3. Kise Bond
    4. Jeong Y. Lim
    5. Ganesh Cherala
    6. David F. Archer
    7. Jeffrey T. Jensen

  • Drug Eluting Embolization Particles for Permanent Contraception

    ACS Biomaterials Science and Engineering
    1. Hannah Vanbenschoten
    2. Shan Yao
    3. Jeffrey T. Jensen
    4. Kim A. Woodrow

  • Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens

    Contraception
    1. Carolyn L. Westhoff
    2. David F. Archer
    3. Kurt Barnhart
    4. Philip Darney
    5. Melissa Gilliam
    6. Jeffrey Jensen
    7. Anita Nelson
    8. Stephanie Teal
    9. Michael Thomas
    10. Jack Hu
    11. Jill Brown
    12. Diana L. Blithe

  • Mucus secretions from a conditionally reprogrammed primary endocervical cell culture

    F and S Science
    1. Daye Park
    2. Ashok Reddy
    3. Phillip A. Wilmarth
    4. Jeffrey Jensen
    5. Leo Han

  • Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate

    Contraception: X
    1. Douglas J. Taylor
    2. Vera Halpern
    3. Vivian Brache
    4. Luis Bahamondes
    5. Jeffrey T. Jensen
    6. Laneta J. Dorflinger

  • Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol/drospirenone on bleeding patterns in healthy women

    Contraception
    1. Andrew M. Kaunitz
    2. Sharon L. Achilles
    3. János Zatik
    4. Steven Weyers
    5. Terhi Piltonen
    6. Larisa Suturina
    7. Inna Apolikhina
    8. Celine Bouchard
    9. Melissa J. Chen
    10. Jeffrey T. Jensen
    11. Carolyn L. Westhoff
    12. Maud Jost
    13. Jean Michel Foidart
    14. Mitchell D. Creinin

  • Pooled efficacy results of estetrol/drospirenone combined oral contraception phase 3 trials

    Contraception
    1. Jeffrey T. Jensen
    2. Andrew M. Kaunitz
    3. Sharon L. Achilles
    4. János Zatik
    5. Steven Weyers
    6. Terhi Piltonen
    7. Larisa Suturina
    8. Inna Apolikhina
    9. Céline Bouchard
    10. Melissa J. Chen
    11. Dan Apter
    12. Maud Jost
    13. Jean–Michel M. Foidart
    14. Mitchell D. Creinin

  • Systemic polidocanol from intravenous or pressurized intrauterine administration produces reversible cardiovascular toxicity

    JVS-Vascular Science
    1. Jeffrey T. Jensen
    2. Philberta Leung
    3. Mackenzie Roberts
    4. Jian Guo
    5. Shan Yao
    6. Emily Mishler
    7. Tanner Grenz
    8. James Hodovan
    9. Ov D. Slayden
    10. Jonathan R. Lindner

  • The use of serum segesterone acetate levels to assess adherence of trial participants with a contraceptive vaginal ring

    Contraception
    1. Rebecca L. Thompson
    2. Jack Hu
    3. Philip Custodio
    4. Clint Dart
    5. Jeffrey T. Jensen

  • Tolerability and safety of the estetrol/drospirenone combined oral contraceptive

    Contraception
    1. Melissa J. Chen
    2. Jeffrey T. Jensen
    3. Andrew M. Kaunitz
    4. Sharon L. Achilles
    5. János Zatik
    6. Steven Weyers
    7. Terhi Piltonen
    8. Larisa Suturina
    9. Inna Apolikhina
    10. Celine Bouchard
    11. David F. Archer
    12. Maud Jost
    13. Jean Michel Foidart
    14. Mitchell Creinin